Fidelis Recall Takes Smaller-Than-Expected Bite Out Of Medtronic’s Sales
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's Fidelis implantable defibrillator lead recall in October cost the company $130 million in lost sales in its most recent fiscal quarter, which is substantially less than the $150 million-$250 million it originally forecasted